Overview A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON) Status: RECRUITING Trial end date: 2026-12-01 Target enrollment: Participant gender: Summary This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.Phase: PHASE2 Details Lead Sponsor: Priovant Therapeutics, Inc.